Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,EDSA,16839834,13255600,7975304,,-2259187,,-2259987,1535127,0,-9510431,-9510431,,,,,,800,0,9510431,0,7251244,,-2259987,-2259987,2432950,2914482,4728906,19272784,24001690,34602637,-18050078,47646,-194257,10966194,4620135,-194257,150381,21418359,7810139,4543123,3624018,-2963,-15346,11942826,-1551214,12265640,4660901,-99434,-7179528,29804,-7489587,-307468,467438,-2963,16798224,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.908,0.4711111,4.05 - 10.13,-4.172,-0.41184598,4.05,10.13,1560124800,1620995400,1628598600,1629117000,-0.726,-0.96,1.4991533,5.92 - 6.25,5.87,5.95,6.03,8,40,finmb_313039720,NasdaqCM,"Edesa Biotech, Inc.",USD,103468,95550,-6.20625,0.564,4.8261113,1.1318889,0.23453435,5.517391,0.44060898,0.079858206,78976864,10.56383,15,America/New_York,EDT,-14400000,2,NCM,REGULAR,us_market,"Edesa Biotech, Inc.",5.958,1630507572,0.0880003,5.93,6.25,5.92,159969,1.53,,,10.13,4.05,4.83,5.52,103.47k,95.55k,13.26M,,7.86M,32.84%,14.60%,52.63k,0.2,0.67%,0.40%,54.06k,,,,,,0.00%,"Jun 09, 2019",,1:6,"Jun 09, 2019","Sep 29, 2020","Mar 30, 2021",0.00%,"-14,393.94%",-62.84%,-66.23%,110.48k,0.01,,311.2k,-15.79M,-8.68M,-0.73,,10.97M,0.83,138.14k,0.72,4.64,0.56,-13.22M,-14.46M,Value,L3R 5H6,Healthcare,12,"Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.",Markham,289 800 9600,ON,1609372800,Canada,http://www.edesabiotech.com,86400,100 Spy Court,Biotechnology
t-1,EDSA,5426981,13255600,1379654,,-2637612,,-2637612,1234148,0,-2613802,-2613802,,,,,,0,0,2613802,0,-23810,,-2637612,-2637612,2458243,2156719,1033332,7885224,10290769,21696459,-15784177,47082,-183777,6305293,906327,-183777,165201,7667325,168030,831450,-672234,-1135,15346,1994972,-377308,2021566,-908402,108290,-3010529,28843,-75127,-41940,722909,-1135,6760998,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.908,0.4711111,4.05 - 10.13,-4.172,-0.41184598,4.05,10.13,1560124800,1620995400,1628598600,1629117000,-0.726,-0.96,1.4991533,5.92 - 6.25,5.87,5.95,6.03,8,40,finmb_313039720,NasdaqCM,"Edesa Biotech, Inc.",USD,103468,95550,-6.20625,0.564,4.8261113,1.1318889,0.23453435,5.517391,0.44060898,0.079858206,78976864,10.56383,15,America/New_York,EDT,-14400000,2,NCM,REGULAR,us_market,"Edesa Biotech, Inc.",5.958,1630507572,0.0880003,5.93,6.25,5.92,159969,1.53,,,10.13,4.05,4.83,5.52,103.47k,95.55k,13.26M,,7.86M,32.84%,14.60%,52.63k,0.2,0.67%,0.40%,54.06k,,,,,,0.00%,"Jun 09, 2019",,1:6,"Jun 09, 2019","Sep 29, 2020","Mar 30, 2021",0.00%,"-14,393.94%",-62.84%,-66.23%,110.48k,0.01,,311.2k,-15.79M,-8.68M,-0.73,,10.97M,0.83,138.14k,0.72,4.64,0.56,-13.22M,-14.46M,Value,L3R 5H6,Healthcare,12,"Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.",Markham,289 800 9600,ON,1609372800,Canada,http://www.edesabiotech.com,86400,100 Spy Court,Biotechnology
t-2,EDSA,4147639,13255600,1154771,,-2014498,,-2014498,853889,-1814,-2010474,-2010474,,,,,,0,500,2010974,2314,-4024,,-2014498,-2014498,2483536,1550480,1654245,6631175,10762375,18500853,-13132954,29928,-287204,7213695,1529857,-287204,174821,8104018,87446,1460127,525215,3541,88,3228442,-269401,3235375,1573000,13954,-1672937,29020,-29230,-7021,85957,-4031,6574161,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.908,0.4711111,4.05 - 10.13,-4.172,-0.41184598,4.05,10.13,1560124800,1620995400,1628598600,1629117000,-0.726,-0.96,1.4991533,5.92 - 6.25,5.87,5.95,6.03,8,40,finmb_313039720,NasdaqCM,"Edesa Biotech, Inc.",USD,103468,95550,-6.20625,0.564,4.8261113,1.1318889,0.23453435,5.517391,0.44060898,0.079858206,78976864,10.56383,15,America/New_York,EDT,-14400000,2,NCM,REGULAR,us_market,"Edesa Biotech, Inc.",5.958,1630507572,0.0880003,5.93,6.25,5.92,159969,1.53,,,10.13,4.05,4.83,5.52,103.47k,95.55k,13.26M,,7.86M,32.84%,14.60%,52.63k,0.2,0.67%,0.40%,54.06k,,,,,,0.00%,"Jun 09, 2019",,1:6,"Jun 09, 2019","Sep 29, 2020","Mar 30, 2021",0.00%,"-14,393.94%",-62.84%,-66.23%,110.48k,0.01,,311.2k,-15.79M,-8.68M,-0.73,,10.97M,0.83,138.14k,0.72,4.64,0.56,-13.22M,-14.46M,Value,L3R 5H6,Healthcare,12,"Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.",Markham,289 800 9600,ON,1609372800,Canada,http://www.edesabiotech.com,86400,100 Spy Court,Biotechnology
t-3,EDSA,2833309,13255600,1143868,,-1765763,,-1765763,733079,108513,-1768434,-1768434,,,,,,0,109985,1878419,1472,2671,,-1765763,-1765763,2508829,1951683,1122565,5342138,8922754,14784903,-11099552,29320,-294896,5640695,983078,-294896,193118,6220807,56471,916369,397882,-26827,29660,-27494,-123123,3235375,-1349235,58330,-1353244,23489,29215,-57154,85056,-4031,5237729,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.908,0.4711111,4.05 - 10.13,-4.172,-0.41184598,4.05,10.13,1560124800,1620995400,1628598600,1629117000,-0.726,-0.96,1.4991533,5.92 - 6.25,5.87,5.95,6.03,8,40,finmb_313039720,NasdaqCM,"Edesa Biotech, Inc.",USD,103468,95550,-6.20625,0.564,4.8261113,1.1318889,0.23453435,5.517391,0.44060898,0.079858206,78976864,10.56383,15,America/New_York,EDT,-14400000,2,NCM,REGULAR,us_market,"Edesa Biotech, Inc.",5.958,1630507572,0.0880003,5.93,6.25,5.92,159969,1.53,,,10.13,4.05,4.83,5.52,103.47k,95.55k,13.26M,,7.86M,32.84%,14.60%,52.63k,0.2,0.67%,0.40%,54.06k,,,,,,0.00%,"Jun 09, 2019",,1:6,"Jun 09, 2019","Sep 29, 2020","Mar 30, 2021",0.00%,"-14,393.94%",-62.84%,-66.23%,110.48k,0.01,,311.2k,-15.79M,-8.68M,-0.73,,10.97M,0.83,138.14k,0.72,4.64,0.56,-13.22M,-14.46M,Value,L3R 5H6,Healthcare,12,"Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.",Markham,289 800 9600,ON,1609372800,Canada,http://www.edesabiotech.com,86400,100 Spy Court,Biotechnology
